PDPN and Atherosclerotic lesion: These findings suggest that podoplanin cannot have access to CLEC-2 unless the plaque ruptures and that S100A13, but not podoplanin, is expressed on the surface of atherosclerotic lesions and can interact with CLEC-2 in the blood flow.